Therapy of small cell lung cancer with emphasis on oral
topotecan

J 2010

Therapy of small cell lung cancer with emphasis on oral topotecan

PIRKER, Robert, Peter BERZINEC, S. BRINCAT, P. KASAN, G. OSTOROS et. al.

Basic information

Original name

Therapy of small cell lung cancer with emphasis on oral topotecan

Authors

PIRKER, Robert (40 Austria, guarantor), Peter BERZINEC (703 Slovakia), S. BRINCAT (470 Malta), P. KASAN (703 Slovakia), G. OSTOROS (348 Hungary), M. PESEK (203 Czech Republic), S. PLATE (428 Latvia), G. PURKALNE (428 Latvia), R. ROONEEM (246 Finland), Jana SKŘIČKOVÁ (203 Czech Republic, belonging to the institution), D. STANCULEANU (642 Romania), C. TIMCHEVA (100 Bulgaria), V. TZEKOVA (100 Bulgaria), B. ZAKOTNIK (705 Slovenia), Ch.C. ZIELINSKI (40 Austria) and M. ZWITTER (705 Slovenia)

Edition

Lung Cancer, 2010, 0169-5002

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30200 3.2 Clinical medicine

Country of publisher

Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 3.356

RIV identification code

RIV/00216224:14110/10:00051508

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.lungcan.2010.05.020

UT WoS

000282503700002

Keywords in English

Chemotherapy; New drugs; Thoracic radiotherapy; Brain irradiation; Second-line therapy; Topotecan

Abstract

V originále

Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer.

Citovat

PIRKER, Robert, Peter BERZINEC, S. BRINCAT, P. KASAN, G. OSTOROS, M. PESEK, S. PLATE, G. PURKALNE, R. ROONEEM, Jana SKŘIČKOVÁ, D. STANCULEANU, C. TIMCHEVA, V. TZEKOVA, B. ZAKOTNIK, Ch.C. ZIELINSKI and M. ZWITTER. Therapy of small cell lung cancer with emphasis on oral topotecan. Lung Cancer. 2010, vol. 70, No 1, p. 7-13. ISSN 0169-5002. Available from: https://dx.doi.org/10.1016/j.lungcan.2010.05.020.

@article{906668,
   author = {Pirker, Robert and Berzinec, Peter and Brincat, S. and Kasan, P. and Ostoros, G. and Pesek, M. and Plate, S. and Purkalne, G. and Rooneem, R. and Skřičková, Jana and Stanculeanu, D. and Timcheva, C. and Tzekova, V. and Zakotnik, B. and Zielinski, Ch.C. and Zwitter, M.},
   article_number = {1},
   doi = {http://dx.doi.org/10.1016/j.lungcan.2010.05.020},
   keywords = {Chemotherapy; New drugs; Thoracic radiotherapy; Brain irradiation; Second-line therapy; Topotecan},
   language = {eng},
   issn = {0169-5002},
   journal = {Lung Cancer},
   title = {Therapy of small cell lung cancer with emphasis on oral topotecan},
   volume = {70},
   year = {2010}
}

TY  - JOUR
ID  - 906668
AU  - Pirker, Robert - Berzinec, Peter - Brincat, S. - Kasan, P. - Ostoros, G. - Pesek, M. - Plate, S. - Purkalne, G. - Rooneem, R. - Skřičková, Jana - Stanculeanu, D. - Timcheva, C. - Tzekova, V. - Zakotnik, B. - Zielinski, Ch.C. - Zwitter, M.
PY  - 2010
TI  - Therapy of small cell lung cancer with emphasis on oral topotecan
JF  - Lung Cancer
VL  - 70
IS  - 1
SP  - 7-13
EP  - 7-13
SN  - 01695002
KW  - Chemotherapy
KW  - New drugs
KW  - Thoracic radiotherapy
KW  - Brain irradiation
KW  - Second-line therapy
KW  - Topotecan
N2  - Systemic chemotherapy plays the major role in the management of patients with small cell lung cancer. Cisplatin plus etoposide is the most widely used regimen and is considered as standard in patients with limited disease. Cisplatin plus irinotecan improved survival compared to cisplatin plus etoposide in a Japanese trial but failed to do so in two trials in Caucasians. Cisplatin plus topotecan had similar efficacy compared to cisplatin plus etoposide in patients with extensive disease. In the second-line setting, topotecan showed similar efficacy but better tolerability compared to cyclophosphamide, doxorubin plus vincristine. Oral topotecan was as efficacious as its intravenous formulation and was shown to improve survival compared to best supportive care alone in patients previously treated with chemotherapy. Thus topotecan is considered as the standard second-line chemotherapy in patients with small cell lung cancer.
ER  -

PIRKER, Robert, Peter BERZINEC, S. BRINCAT, P. KASAN, G. OSTOROS, M. PESEK, S. PLATE, G. PURKALNE, R. ROONEEM, Jana SKŘIČKOVÁ, D. STANCULEANU, C. TIMCHEVA, V. TZEKOVA, B. ZAKOTNIK, Ch.C. ZIELINSKI and M. ZWITTER. Therapy of small cell lung cancer with emphasis on oral topotecan. \textit{Lung Cancer}. 2010, vol.~70, No~1, p.~7-13. ISSN~0169-5002. Available from: https://dx.doi.org/10.1016/j.lungcan.2010.05.020.

Detailed Information on Publication Record